Boehringer Ingelheim steps up effort with Global Support Program

Boehringer Ingelheim has significantly stepped up its support to the fight against COVID-19. A Global Support Program has been set up to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.

"As a pharmaceuticals company, we feel a strong commitment to offer our help to patients, and to those who help them," said Hubertus von Baumbach, Chairman of the Board of Managing Directors. "Many of our employees want to participate in the program: we offer support through donations and paid-leave volunteering, engage in significant scientific projects and bring relief to communities in developing regions in Kenya and India, with whom we have a decade-long relationship. All this, plus the drive that I see with colleagues to ensure continued production of medicines, is dedicated to the many, many people who suffer from COVID-19. Our thoughts are with them and their loved ones."

Boehringer Ingelheim initially started a EUR 1 million donations program in January for affected regions in China. With the Corona virus spreading to become a global pandemic, efforts to provide relief and scientific support grew strongly these past few weeks. This ultimately resulted in a Global Support Program with four focus areas:

1. Donations

Boehringer Ingelheim has made available EUR 5.8 million for financial and in-kind donations for local emergency aid across its markets. This includes, for example, protective masks, disinfectants, inhalers and medicines. The company is also working with local organizations that use financial and medicine donations to organize help for patients in their communities.

2. Research for COVID-19 Therapies

Since January, a growing team of currently more than 100 highly engaged Boehringer Ingelheim scientists from all areas of research and development (R&D) have contributed to projects aimed at finding potential treatment solutions for COVID-19. "All of us are thinking about how we can find new ways to tackle this virus. This has led to a broad program pursuing many approaches in parallel," says Dr Cyrille Kuhn, Executive Director Research, who leads Boehringer Ingelheim’s COVID-19 efforts since January.

Moreover, an increasing number of collaboration partners and service providers is bolstering the team’s efforts. Most of the projects are part of larger collaborative efforts with academia, biotech and other pharma companies. Among them is a call by the Innovative Medicines Initiative of the EU (IMI), to which Boehringer Ingelheim is planning to commit in excess of 11,000 work hours in R&D. The company also joined the Bill & Melinda Gates Foundation COVID-19 Therapeutic Accelerator.

In addition, Boehringer Ingelheim supports scientists worldwide with its open innovation portal opnMe.com, which offers 6 anti-viral compounds out of 43 high quality pharmacological tool compounds at no cost for testing of research hypotheses.

As this work evolves, the company will commit further experts from multiple disciplines, as well as increased lab capacity.

3. Volunteering

In many communities, helping hands from volunteers, for example with a medical or nursing background, are urgently needed. Boehringer Ingelheim offers all of its 51,000 employees the opportunity to take up to 10 days of paid leave to join approved external organizations as a volunteer to bring COVID-19 relief. Employees who are unable to perform their work on-site or from home, are given the opportunity to volunteer for longer while paid their regular salaries, until they can resume their work.

4. Making More Health relief fund

An EUR 580,000 relief fund has been launched to support the global Making More Health (MMH) network of social entrepreneurs in Kenya and India, as well as the communities in which they live and work. The fund will help social enterprises and their activities to sustain a longer period of low economic activity and will invest in social entrepreneurial ideas that can help reduce the risk of the Corona virus spreading.

"Especially in times like these Social Entrepreneurs around the world are well placed to leverage their proximity to those in needs," said Jean Scheftsik de Szolnok, member of the Board of Managing Directors and one of the founders of the MMH movement. "MMH communities such as self-help groups in India or people suffering from albinism in Kenya, have started to produce soap and at the same time education programs on hygiene awareness in their neighborhoods." Over the past years more than 750 students at the MMH school and some 1,000 families in farmer cooperatives have been trained in hygiene and soap production in Kenya and India.

Boehringer Ingelheim is committed to the global community and to the well-being of people and animals. As a research-driven company, it started its support activities in January and will continue to do what it can to deliver a meaningful contribution in the fight against COVID-19. The company continues to support healthcare systems by reliably supplying drugs and through our research.

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Our significant investment in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
 

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.